1,720,996 research outputs found
Mutations in the coding region of the FOXL2 gene are not a major cause of idiopathic premature ovarian failure
No full textEFFICACY OF PLACEBO IN THE TREATMENT OF PATIENTS WITH AMENORRHEA
No full textThirty-two amenorrheic patients were treated with a tablet oral placebo preparation for a period varying from 30 to 180 days. Another 24 amenorrheic patients were also treated with a placebo administered i.m. for a period varying from 30 to 120 days. As a consequence of the treatment, 27 patients (48%) had menstrual bleedings. The progestogen withdrawal test responsive patients were more responsive to placebo (73 vs. 14% in the progestogen withdrawal test nonresponsive, p < 0.001). The time lag between starting the medication and the first bleeding varied between 4 and 120 days with a mean value of 33.9 (SD 26.3). Oral placebo was more effective than the intramuscular form (56 vs. 38%, p < 0.05)
Plasma Low-Density Lipoprotein Cholesterol and Bone Mass Densitometry in Postmenopausal Women.
No full textRisk factors for seromucinous benign ovarian cysts in northern Italy
No full textStudy objective-To analyse risk factors for seromucinous benign ovarian cysts. Design-Between 1984 and 1994 a case-control study was carried out. Cases were 225 women aged less than 65 years with a histologically confirmed diagnosis of benign seromucinous ovarian cysts admitted to a network of obstetrics and gynaecology departments in Milan. Controls were a random sample of 450 women admitted for acute conditions that were not gynaecological, hormonal, or neoplastic. They were interviewed within the framework of a case-control study of female genital neoplasms. Setting-Network of hospitals in the greater Milan area, Italy. Main results-The risk of seromucinous benign ovarian cysts was higher in more educated women than in women with fewer than seven years of schooling. The odds ratios (OR) for seromucinous ovarian cysts were 1.3 and 1.4 respectively in women reporting 7-11 and greater than or equal to 12 years of schooling, and the trend in risk was statistically significant (chi(1)(2), trend 5.20, p<0.05). There was no clear relationship between the risk of seromucinous ovarian cysts and marital status, age at first marriage, oral contraceptive use, smoking, or body mass index. In comparison with women reporting menstrual cycles lasting <28 days, the risks of seromucinous cysts were 1.6, 2.6, and 2.5 respectively in women reporting cycles lasting 28-30, greater than or equal to 31 days, or with totally irregular ones. Among ever married women, nine cases and two controls reported difficulty in conception, and the corresponding OR for seromucinous cysts was 17.7 (95% confidence interval 4.2, 83.8). Conclusions-The risk of seromucinous benign ovarian tumours is greater in more educated women and in women with a history of infertility and with long or irregular menstrual cycles
Treatment for infertility and risk of invasive epithelial ovarian cancer
No full textThe relationship between the use of fertility drugs and the risk of ovarian cancer was analysed using data from an Italian case-control study. The study comprised 971 women below the age of 75 years with histologically confirmed invasive epithelial ovarian cancer diagnosed within the year before the interview. The controls were 2758 women admitted to the same network of hospitals where the cases of ovarian cancer had been identified. Five cases (0.5%) and 11 controls (0.4%) reported use of fertility drugs. In comparison with women who had never used fertility drugs, the multivariate odds ratio (OR) for women who had taken fertility drugs was 1.1 [95% confidence interval (CI) 0.4-3.3]. The OR were 0.7 (95% CI 0.1-7.9) and 1.0 (95% CI 0.2-3.8) for women who had used fertility drugs for <6 and greater than or equal to 6 cycles respectively. Considering the 14 cases and 45 controls reporting difficulty in conception, the risk of ovarian cancer was 0.5 (95% CI 0.1-3.6) for women who reported use of fertility drugs. Considering nulliparous women only, the estimated OR of ovarian cancer for any fertility drug use was 0.6 (95% CI 0.1-3.5). Although the present results have limitations in terms of statistical power and available information, they provide reassuring evidence of the absence of a strong association between fertility drugs and subsequent risk of developing epithelial ovarian cancer
Mutation analysis of the inhibin alpha gene in a cohort of Italian women affected by ovarian failure
No full textEffect of oral and transdermal hormone replacement therapy on homocysteine levels: a randomized clinical trial.
No full textMolecular definition of Xq common-deleted region in patients affected by premature ovarian failure
No full text
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
- …
